COVID-19 vaccine maker Novavax (NASDAQ:NVAX) has slashed about $50M in costs in Q1 2023, and the biotech plans to reduce costs even further, Reuters reported quoting the company CEO John Jacobs as saying during an interview on Wednesday.
“We’re looking at everything from buildings, leases, land, headcount, and contractors, every aspect of our company and the way we work,” he added.
Jacobs, who took over Novavax (NVAX) leadership early this month after long-time CEO Stanley Erck retired, said that the company is in regular discussions with the FDA regarding the design of its 2023 COVID-19 booster shot.
READ FULL ARTICLE HERE
